The Competition Commission of India (CCI) has cleared Novartis and GlaxoSmithKline's multi-segment transactions in India and ruled out any input/customer ''foreclosure'' concerns as a result of the firms' combination in the area of vaccines.
The Indian deals are a result of a global transaction announced in April under which Novartis was to divest its...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
